AIM Vaccine Co., Ltd. (06660.HK) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	2.3B	1.2B	1.3B	1.2B	1.3B
Cost of Revenue	704.6M	405.5M	331.5M	1.8B	236.4M
Gross Profit	1.6B	760.2M	953.5M	(611.2M)	1.0B
Operating Expenses
R&D Expense	418.6M	191.3M	363.1M	2.1B	500.3M
SG&A Expense	1.5B	776.8M	825.4M	748.3M	943.9M
General & Admin Expense	414.9M	256.3M	282.7M	254.3M	450.8M
Selling & Marketing Expense	837.9M	527.5M	542.7M	494.0M	493.2M
Other Expenses	—	—	(24.1M)	4.2M	27.2M
Total Operating Expenses	2.0B	968.1M	1.2B	2.9B	1.5B
Cost and Expenses	2.7B	1.4B	1.5B	4.7B	1.7B
Operating Income (EBIT)	(402.7M)	(202.5M)	(210.9M)	(3.5B)	(384.3M)
Non-Operating
Interest Income	1.5M	3.3M	7.5M	10.7M	10.7M
Interest Expense	112.9M	56.3M	60.8M	43.8M	25.7M
Net Interest Income	(111.3M)	(53.0M)	(53.3M)	(33.1M)	(15.0M)
Other Non-Op Income/Expense	(605.8M)	(544.2M)	(79.8M)	1.2B	(49.8M)
Non-Operating Income (excl Interest)	—	—	19.0M	(1.3B)	24.1M
EBT (Pre-Tax Income)	(1.0B)	(746.7M)	(290.7M)	(2.3B)	(434.2M)
Income Tax Expense	(22.8M)	(22.2M)	(12.2M)	(320.4M)	(203.5M)
Bottom Line
Net Income	(934.6M)	(675.5M)	(277.2M)	(1.3B)	(319.6M)
Earnings from Cont. Ops	(985.7M)	(724.5M)	(278.5M)	(2.0B)	(230.6M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(934.6M)	(675.5M)	(277.2M)	(1.3B)	(319.6M)
Per Share
Basic EPS	(HK$0.77)	(HK$0.55)	(HK$0.23)	(HK$1.07)	(HK$0.31)
Diluted EPS	(HK$0.77)	(HK$0.55)	(HK$0.23)	(HK$1.07)	(HK$0.31)
Revenue Per Share	HK$1.84	HK$0.95	HK$1.07	HK$0.98	HK$1.23
Shares
Basic Shares Outstanding	1.2B	1.2B	1.2B	1.2B	1.0B
Diluted Shares Outstanding	1.2B	1.2B	1.2B	1.2B	1.0B
Profitability Metrics
EBITDA	(142.7M)	(89.4M)	(98.8M)	(2.1B)	(242.0M)
D&A	265.4M	118.5M	131.1M	174.7M	166.4M
EBIT	(408.1M)	(207.9M)	(229.9M)	(2.2B)	(408.5M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026